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airway pressure. A randomized, controlled cross-over
study’† by M.A. Arias et al., on page 1106
Man spends one-third of his life in sleep. Sleep is not a
passive state but rather an active process that if disturbed
on a regular basis can even constitute a threat to man’s
health. Sleep medicine is a fairly new discipline and until
1980 there were only few scientiﬁc publications on the
theme. Obstructive sleep apnoea syndrome was ﬁrst
described in 1976 by Guilleminault. Since then it has
turned out to be a disorder that does not only cause a
noise problem for the patient’s bed partner but also consti-
tutes a serious disease of overriding importance.
Obstructive sleep apnoea syndrome is highly prevalent:
17–24% of adults have sleep-related breathing disorders
and 2–4% of them suffer from the disease and need treat-
ment.1 In addition, obstructive sleep apnoea is associated
with an increased risk of cardiovascular disease and
stroke, and there is a strong suspicion that untreated sleep-
disordered breathing precipitates greater mortality.2 Gami
et al.3 reviewed polysomnograms and the death certiﬁcates
of 112 Minnesota residents who had undergone polysomno-
graphy and had died suddenly from cardiac causes. They
found that people with obstructive sleep apnoea have a
peak in sudden death from cardiac causes during the sleep-
ing hours, which contrasts strikingly with the nadir of sudden
death from cardiac causes during this period in people
without obstructive sleep apnoea and in the general
population.
Obstructive sleep apnoea is characterized by intrathoracic
pressure swings during obstructed breathing, hypoxaemia as
a result of apnoeic events, and arousals from sleep that
terminate the apnoeas. The resultant hypoxaemia can lead
to nocturnal cardiac ischaemia and ventricular arrhythmias.
Apnoeic episodes elicit increased sympathetic activity,
acute blood pressure elevations, and platelet aggregation.
These factors can all be responsible for the increased
mortality and the increased risk of stroke in sleep apnoea
patients.4
Although the causal association between obstructive sleep
apnoea and night-time hypertension has always been well
accepted, the relation to daytime hypertension was less
clear until recently. This is because of the fact that patients
with hypertension and patients with obstructive sleep
apnoea have common risk factors like obesity (and its
pattern of distribution), alcohol consumption, age, male
gender, and decreased physical activity. Several well-
conducted, large population-based studies have now
been able to prove an independent association with a
dose-response relationship between these two conditions
in man, indicating that obstructive sleep apnoea constitutes
a risk factor for hypertension. These results induced the
National High Blood Pressure Education Program of the
National Heart, Lung, and Blood Institute to publish
updated consensus recommendations for the prevention
and treatment of hypertension and to declare obstructive
sleep apnoea as an identiﬁable cause of hypertension in
their JNC 7 report.5 Given the high prevalence of obstructive
sleep apnoea, this disease could be the most frequent
(treatable) cause of hypertension.
Several investigators have reported an association
between obstructive sleep apnoea and sustained daytime
pulmonary hypertension. Approximately 20% of patients
with obstructive sleep apnoea—as determined by right
heart catheterization—have pulmonary hypertension.6,7
Sustained pulmonary hypertension among these patients is
often related to right ventricular failure. In this context,
the report of Arias et al.8 extends the existing knowledge.
Pulmonary hypertension in patients with obstructive sleep
apnoea is often associated with obesity or chronic obstruc-
tive lung disease. However, Arias et al.8 examined patients
without coexisting cardio-pulmonary disease and they
could demonstrate that the level of pulmonary hypertension
is directly related to the severity of obstructive sleep
apnoea and the presence of left ventricular dysfunction. In
addition, they showed that sustained daytime pulmonary
hypertension in patients with obstructive sleep apnoea can
be reversed after effective continuous positive airway
pressure (CPAP) treatment. The strength of the study of
Arias et al.8 is that their patients randomly received either
sham or effective treatment with CPAP for 12 weeks and
they could show that only effective treatment reduced
pulmonary systolic pressure levels.
The study points out to an effective therapy to reduce the
large burden of heart failure in these patients. In contrast,
screening of heart failure patients for the presence of
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obstructive sleep apnoea may uncover those patients who
take advantage of effective CPAP treatment.
The potential mechanisms of daytime pulmonary hyper-
tension in obstructive sleep apnoea are still under debate.
Serum levels of vascular endothelial growth factor—a
hypoxia-sensitive glycoprotein stimulating neoangiogenesis—
are elevated in patients with obstructive sleep apnoea.9 It
is assumed that the post-capillary component of daytime
pulmonary hypertension is due to diastolic dysfunction and
that the pre-capillary component results from repetitive
hypoxia-reoxygenation during the night, leading to both
pulmonary vasoconstriction and vascular endothelial
remodelling. Furthermore, genetic factors seem to deter-
mine the link between hypoxia and the manifestation of
pulmonary hypertension.
There are still unresolved questions: should all patients
with obstructive sleep apnoea be screened for coexisting
pulmonary hypertension, and should all obstructive sleep
apnoea patients with pulmonary hypertension be treated
with CPAP, even if they are not symptomatic with regard
to daytime sleepiness? Nonetheless, the study by Arias
et al.8 provides a new piece of the puzzle, showing that
obstructive sleep apnoea is not only an underestimated
cardiovascular risk factor, but that there is effective treat-
ment with the chance of modifying the otherwise increased
cardiovascular morbidity and mortality.
Conﬂict of interest: none.
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